More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.77B
EPS
-0.62
P/E ratio
--
Price to sales
0.48
Dividend yield
7.155%
Beta
0.874827
Previous close
$9.16
Today's open
$9.14
Day's range
$8.84 - $9.18
52 week range
$8.14 - $14.76
show more
CEO
Simon D. Campion
Employees
14000
Headquarters
Charlotte, NC
Exchange
Nasdaq Global Select
Shares outstanding
198153678
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Dentsply Sirona: 3 Key Takeaways for Long-Term Investors
Management reduced full-year 2026 sales guidance to approximately $3.5 billion. Wellspect Healthcare revenue grew 10% year over year to $92 million.
The Motley Fool • Nov 16, 2026

New Strong Sell Stocks for November 13th
XRAY, BROS and GECC have been added to the Zacks Rank #5 (Strong Sell) List on November 13, 2026.
Zacks Investment Research • Nov 13, 2026

DENTSPLY SIRONA Inc. (XRAY) Q3 2026 Earnings Call Transcript
DENTSPLY SIRONA Inc. ( XRAY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Suzanne Hatcher Daniel Scavilla - President, CEO, Interim Principal Financial Officer & Director John Fortson - Executive VP & CFO Conference Call Participants Allen Lutz - BofA Securities, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Leah Waldman Bailey - Leerink Partners LLC, Research Division Presentation Operator Good day, and thank you for standing by.
Seeking Alpha • Nov 7, 2026

DENTSPLY SIRONA Q3 Earnings Call Highlights
DENTSPLY SIRONA NASDAQ: XRAY lowered its full-year earnings outlook after third-quarter sales fell across its dental businesses, as pressure from European distributor inventory reductions, the Middle East conflict and higher freight costs offset progress in parts of its U.S. operations.
MarketBeat • Nov 6, 2026

XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook Cut
DENTSPLY SIRONA's Q3 sales decline 7.6% amid dental weakness, while Wellspect growth provides support. The company lowers its 2026 outlook.
Zacks Investment Research • Nov 6, 2026

Dentsply Sirona Reports Third Quarter 2026 Results
News Summary Q3 2026 net sales of $836 million Q3 2026 GAAP gross margin of 52.9% , GAAP diluted loss per share of ($0.01) Q3 2026 adjusted gross margin of 54.5% , adjusted EBITDA margin of 17.3% , adjusted EPS of $0.29 Achieved record quarterly sales for Wellspect Healthcare, with 10.1% as-reported growth; completed the U.S. Surity™ portfolio with the launch of the Surity ™ Urinary Management System Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30 CHARLOTTE, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2026.
GlobeNewsWire • Nov 5, 2026

Dentsply International (XRAY) Q3 Earnings and Revenues Miss Estimates
Dentsply International (XRAY) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.37 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Dentsply (XRAY) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Dentsply (XRAY) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research • Nov 6, 2026

DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock?
DENTSPLY SIRONA faces Q3 earnings pressure from weak dental demand, tariff costs and segment challenges, while Wellspect's growth may offer some relief.
Zacks Investment Research • Nov 4, 2026

Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
PRNewsWire • Oct 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell DENTSPLY SIRONA Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.